MDL 102588

Drug Profile

MDL 102588

Latest Information Update: 22 Sep 1997

Price : $50

At a glance

  • Originator Aventis
  • Class Antidepressants; Antihypertensives; Antimigraines; Anxiolytics
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Serotonin 1C receptor agonists; Serotonin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders; Hypertension; Major depressive disorder; Migraine

Most Recent Events

  • 22 Sep 1997 No-Development-Reported for Hypertension in USA (Unknown route)
  • 22 Sep 1997 No-Development-Reported for Migraine in USA (Unknown route)
  • 22 Sep 1997 No-Development-Reported for Depression in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top